The Health Resources and Services Administration should increase its oversight of private nonprofit hospitals that participate in the 340B drug savings program to ensure they meet eligibility requirements, the Government Accountability Office said in a report released today. Specifically, GAO said HRSA should ensure that it uses reliable information to verify nonprofit status for all nongovernmental hospitals in the program, verify that each of these hospitals has a contract with a state or local government as required, and verify that the contract was in effect prior to the beginning of the audit review period. GAO also recommended that HRSA revise its contract audit procedures and provide auditors with more specific guidance on how to determine whether the contracts require the hospitals to serve low-income individuals not eligible for Medicaid or Medicare. In comments in the report, the Department of Health and Human Services concurred with all of the recommendations except the one to verify that all nongovernmental hospitals have the required contract with a state or local government.
 
AHA Executive Vice President Tom Nickels said, “We look forward to reviewing this report closely. Most important is that tax-exempt hospitals are accountable to the government and their communities in a variety of important ways. For example, they publicly report annually the benefits they provide. In the most recent year for which comprehensive data is available, 340B tax-exempt hospitals provided more than $56 billion in total benefits to their communities.”

Headline
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.In a statement…
Headline
The 4th U.S. Circuit Court of AppealsMay 28 agreed to rehear challenges to 340B contract pharmacy laws from West Virginia and Maryland. In April, a three-judge…
Headline
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 editorial criticizing the 340B Drug…
Headline
The AHA today urged Eli Lilly to abandon its 340B Drug Pricing Program claims-data policy and work with the AHA to develop a functional third-party…
Headline
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to…
Headline
The Washington Post yesterday published a letter to the editor from AHA President and CEO Rick Pollack responding to an April 18 editorial criticizing the 340B…